Cofetuzumab pelidotin

Cofetuzumab pelidotin
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetprotein tyrosine kinase 7
Clinical data
Other namesPF-06647020
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6774H10418N1778O2096S46
Molar mass151776.97 g·mol−1

Cofetuzumab pelidotin (INN;[1] development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer.[2] The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.[3][4]

Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug that then kills the cells. This allows the drug to selectively target the cells that the antibody binds to.[citation needed]

PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer.[5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.[6]

References

[edit]
  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Cofetuzumab Pelidotin, American Medical Association.
  3. ^ "PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
  4. ^ "Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. Retrieved 2017-05-22.
  5. ^ "Antibody-Drug Conjugates (ADCs)" (PDF). Pfizer Oncology.
  6. ^ Patrick M (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. Retrieved 2017-05-22.